title: Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.
abstract: Abacavir's effect on cardiovascular function has not been studied prospectively. We measured augmentation index (a measure of arterial stiffness) in 20 men who switched from abacavir to tenofovir. After 4 weeks, mean augmentation index reduced from 22% by 4% (P = 0.03) and Framingham risk score by 2% (P = 0.01), which was driven by lower total cholesterol (0.8 mmol/l; P = 0.002). Consistent trends were observed through week 24. Changes in C-reactive protein, interleukin-6 and D-dimer were inconsistent and only occurred from week 12. Abacavir may impair cardiovascular function by increasing total cholesterol levels.
authors.affiliation: HIV, Immunology and Infectious Diseases Unit, and Clinical Research Program, Centre for Applied Medical Research, St Vincent's Hospital, Sydney, NSW, Australia.
authors.forename: Kate
authors.initials: K
authors.lastname: Sinn
authors.forename: Robyn
authors.initials: R
authors.lastname: Richardson
authors.forename: Andrew
authors.initials: A
authors.lastname: Carr
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000821:virology; D015224:Dideoxynucleosides / Q000009:adverse effects*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D000068698:Tenofovir; D014655:Vascular Resistance / Q000187:drug effects*; D000099227:Abacavir
chemical_list: D000225:Adenine; D015224:Dideoxynucleosides; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000099227:Abacavir